ARWR Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.50%

Insider Buying (Last 12 Months): $54,990.00

Insider Selling (Last 12 Months): $11,140,210.56

Arrowhead Pharmaceuticals Insider Trading History Chart

Arrowhead Pharmaceuticals Share Price & Price History

^$25.22

▲ +0.22 (0.88%)

As of 05/8/2024 01:00 AM ET

Days: 30 | 90 | 365

The A.I. story nobody is telling you (Read ASAP)

From TradeSmith | Ad

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

Arrowhead Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/2/2024	Victoria Vakiener	Director	Sell	1,799	$23.31	$41,934.69	30,205
3/20/2024	Hongbo Lu	Director	Buy	1,000	$27.50	$27,500.00	33,680
3/18/2024	Hongbo Lu	Director	Buy	1,000	$27.49	$27,490.00	31,680
3/6/2024	Kenneth Allen Myszkowski	CFO	Sell	40,000	$35.19	$1,407,600.00	400,600
1/31/2024	Christopher Richard Anzalone	CEO	Sell	57,499	$32.35	$1,860,092.65	3,715,048
1/12/2024	James C. Hamilton	Insider	Sell	7,940	$36.89	$292,906.60	210,851
1/11/2024	Douglas B Given	Director	Sell	2,911	$38.06	$110,792.66	129,711
1/5/2024	James C. Hamilton	Insider	Sell	32,143	$35.18	$1,130,790.74	218,791
1/5/2024	Kenneth Allen Myszkowski	CFO	Sell	16,104	$35.27	$567,988.08	440,600
1/5/2024	Patrick C. O'Brien	COO	Sell	22,841	$35.27	$805,602.07	464,385
1/3/2024	James C. Hamilton	Insider	Sell	6,300	$32.19	$202,797.00	175,934
1/3/2024	Patrick C. O'Brien	COO	Sell	8,749	$32.28	$282,417.72	403,826
1/2/2024	Christopher Richard Anzalone	CEO	Sell	9,952	$31.01	$308,611.52	3,715,048
12/20/2023	Christopher Richard Anzalone	CEO	Sell	12,000	$28.54	$342,480.00	3,725,000
11/20/2023	Javier San Martin	Insider	Sell	19,700	$28.80	$567,360.00	131,800
10/25/2023	Christopher Richard Anzalone	CEO	Sell	24,338	$24.21	$589,222.98	3,737,000
9/28/2023	Victoria Vakiener	Director	Sell	1,550	$26.33	$40,811.50	21,734
9/18/2023	Christopher Richard Anzalone	CEO	Sell	57,755	$28.12	$1,624,070.60	3,761,338
7/3/2023	Tracie Oliver	Insider	Sell	8,925	$35.31	$315,141.75	61,575
6/30/2023	James C. Hamilton	Insider	Sell	3,000	$35.53	$106,590.00	188,484
6/27/2023	Kenneth Allen Myszkowski	CFO	Sell	15,000	$36.20	$543,000.00	381,704
5/5/2023	Douglas B Given	Director	Sell	6,500	$40.90	$265,850.00	117,635
5/3/2023	Christopher Richard Anzalone	CEO	Sell	54,928	$39.14	$2,149,881.92	3,761,338
3/3/2023	Adeoye Y. Olukotun	Director	Sell	11,350	$32.65	$370,577.50	7,867
2/27/2023	Douglas B Given	Director	Sell	875	$32.62	$28,542.50	13,000
1/9/2023	William D. Waddill	Director	Sell	3,200	$30.00	$96,000.00	28,950
1/5/2023	James C. Hamilton	Insider	Sell	13,803	$37.40	$516,232.20	191,484
1/5/2023	Patrick C. O'Brien	COO	Sell	15,000	$37.39	$560,850.00	413,375
1/3/2023	James C. Hamilton	Insider	Sell	10,338	$38.38	$396,772.44	145,287
1/3/2023	Patrick C. O'Brien	COO	Sell	17,500	$38.33	$670,775.00	363,375
12/29/2022	Kenneth Allen Myszkowski	CFO	Sell	30,625	$40.00	$1,225,000.00	336,704
11/21/2022	Javier San Martin	Insider	Sell	19,500	$29.99	$584,805.00	91,500
2/11/2022	Christopher Richard Anzalone	CEO	Sell	146,388	$51.91	$7,599,001.08
1/5/2022	Kenneth Allen Myszkowski	CFO	Sell	40,000	$61.70	$2,468,000.00
1/5/2022	Patrick C. O'Brien	General Counsel	Sell	32,500	$61.72	$2,005,900.00
1/4/2022	James C. Hamilton	SVP	Sell	19,375	$65.49	$1,268,868.75
1/3/2022	William D. Waddill	Director	Sell	4,500	$64.72	$291,240.00
12/28/2021	Douglas B Given	Director	Buy	655	$66.37	$43,472.35
12/15/2021	Christopher Richard Anzalone	CEO	Sell	60,000	$67.56	$4,053,600.00
11/19/2021	Javier San Martin	Insider	Sell	19,500	$69.31	$1,351,545.00
10/22/2021	Christopher Richard Anzalone	CEO	Sell	50,000	$65.63	$3,281,500.00
10/20/2021	Christopher Richard Anzalone	CEO	Sell	15,000	$66.23	$993,450.00
9/13/2021	Adeoye Y. Olukotun	Director	Sell	5,000	$63.76	$318,800.00
6/24/2021	Marianne De Backer	Director	Sell	5,000	$89.85	$449,250.00
6/22/2021	Douglass B. Given	Director	Sell	4,500	$89.21	$401,445.00
6/22/2021	James Hassard	Insider	Sell	3,625	$89.22	$323,422.50

Elon Musk Secret Crypto Plot Exposed

From Crypto 101 Media | Ad

Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.

Click here now to get your copy.

SEC Filings (Institutional Ownership Changes) for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

62.61% of Arrowhead Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Arrowhead Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/8/2024	ProShare Advisors LLC	35,592	$1.02M	0.0%	+21.7%	0.029%
5/8/2024	US Bancorp DE	43,796	$1.25M	0.0%	-5.2%	0.035%
5/8/2024	Russell Investments Group Ltd.	242,636	$6.94M	0.0%	-2.1%	0.196%
5/8/2024	Headlands Technologies LLC	2,417	$69K	0.0%	+7,696.8%	0.002%
5/7/2024	Susquehanna Fundamental Investments LLC	128,083	$3.66M	0.2%	N/A	0.103%
5/7/2024	Swiss National Bank	243,300	$6.96M	0.0%	+21.2%	0.196%
5/7/2024	Nvwm LLC	27,581	$0.79M	0.2%	N/A	0.022%
5/7/2024	SG Americas Securities LLC	7,355	$0.21M	0.0%	-78.8%	0.006%
5/6/2024	Texas Permanent School Fund Corp	108,433	$3.10M	0.0%	+17.3%	0.088%
5/3/2024	Essex Investment Management Co. LLC	72,299	$2.07M	0.4%	N/A	0.058%
5/2/2024	Mutual of America Capital Management LLC	73,826	$2.11M	0.0%	+11.5%	0.060%
5/2/2024	Nordea Investment Management AB	153,357	$4.45M	0.0%	-1.8%	0.124%
5/1/2024	BNP Paribas Financial Markets	116,091	$3.32M	0.0%	-52.3%	0.094%
5/1/2024	Oak Ridge Investments LLC	41,932	$1.20M	0.1%	-3.9%	0.034%
5/1/2024	Mirae Asset Global Investments Co. Ltd.	327,782	$9.38M	0.0%	+67.2%	0.265%
4/30/2024	Retirement Systems of Alabama	348,784	$9.98M	0.0%	+6.5%	0.282%
4/30/2024	Commonwealth Equity Services LLC	33,413	$0.96M	0.0%	-1.5%	0.027%
4/29/2024	Principal Financial Group Inc.	484,120	$13.85M	0.0%	+17.5%	0.391%
4/29/2024	China Universal Asset Management Co. Ltd.	23,838	$0.68M	0.1%	+91.8%	0.019%
4/26/2024	Securian Asset Management Inc.	10,100	$0.29M	0.0%	+12.5%	0.008%
4/26/2024	Yousif Capital Management LLC	57,393	$1.64M	0.0%	+9.9%	0.046%
4/25/2024	New York State Teachers Retirement System	138,683	$3.97M	0.0%	+2.1%	0.112%
4/25/2024	WCM Investment Management LLC	225,583	$6.45M	0.0%	+30.5%	0.182%
4/24/2024	Assenagon Asset Management S.A.	344,467	$9.85M	0.0%	+796.9%	0.278%
4/23/2024	Louisiana State Employees Retirement System	35,700	$1.02M	0.0%	+18.6%	0.029%
4/23/2024	Amalgamated Bank	64,664	$1.85M	0.0%	-3.0%	0.052%
4/23/2024	Wealth Effects LLC	164,460	$4.70M	1.7%	+1.6%	0.133%
4/19/2024	State of Alaska Department of Revenue	13,437	$0.38M	0.0%	+16.1%	0.011%
4/18/2024	Myecfo LLC	18,497	$0.53M	0.3%	N/A	0.015%
4/18/2024	State of Michigan Retirement System	30,470	$0.87M	0.0%	+18.7%	0.025%
4/17/2024	Hennion & Walsh Asset Management Inc.	45,734	$1.31M	0.1%	+11.0%	0.037%
4/12/2024	Global Assets Advisory LLC	40,242	$1.15M	0.0%	N/A	0.032%
3/21/2024	Healthcare of Ontario Pension Plan Trust Fund	95,000	$2.91M	0.0%	+63.8%	0.077%
3/11/2024	Vanguard Group Inc.	10,672,076	$326.57M	0.0%	-1.7%	8.613%
3/1/2024	Goldman Sachs Group Inc.	1,061,967	$32.50M	0.0%	+136.6%	0.857%
2/28/2024	American International Group Inc.	194,208	$5.94M	0.0%	-3.2%	0.157%
2/26/2024	Neo Ivy Capital Management	1,337	$41K	0.1%	N/A	0.001%
2/20/2024	Eventide Asset Management LLC	313,289	$9.59M	0.2%	N/A	0.253%
2/20/2024	Quarry LP	2,400	$73K	0.0%	-51.6%	0.002%
2/14/2024	Avidity Partners Management LP	714,000	$21.85M	0.8%	-32.9%	0.576%
2/14/2024	Avoro Capital Advisors LLC	1,130,000	$34.58M	0.5%	+100.0%	0.912%
2/14/2024	Sectoral Asset Management Inc.	8,182	$0.25M	0.1%	-94.8%	0.007%
2/13/2024	Capital International Investors	1,277,560	$39.09M	0.0%	+55.2%	1.031%
2/13/2024	Rafferty Asset Management LLC	365,087	$11.17M	0.0%	+22.6%	0.295%
2/13/2024	NEOS Investment Management LLC	11,712	$0.36M	0.0%	N/A	0.009%
2/13/2024	Campbell & CO Investment Adviser LLC	15,961	$0.49M	0.0%	N/A	0.013%
2/12/2024	Eagle Asset Management Inc.	553,860	$16.95M	0.1%	+11.3%	0.447%
2/9/2024	US Bancorp DE	46,205	$1.41M	0.0%	-2.0%	0.037%
2/9/2024	Ontario Teachers Pension Plan Board	6,562	$0.20M	0.0%	N/A	0.005%
2/9/2024	Quest Partners LLC	1,476	$45K	0.0%	N/A	0.001%
2/9/2024	Corient Private Wealth LLC	41,386	$1.27M	0.0%	-1.5%	0.033%
2/9/2024	UBS Group AG	508,586	$15.56M	0.0%	+37.6%	0.410%
2/9/2024	Norges Bank	1,321,927	$40.45M	0.0%	N/A	1.067%
2/8/2024	Panagora Asset Management Inc.	85,262	$2.61M	0.0%	-58.8%	0.079%
2/8/2024	Fiera Capital Corp	58,036	$1.78M	0.0%	-1.7%	0.054%
2/8/2024	Vanguard Personalized Indexing Management LLC	10,085	$0.31M	0.0%	N/A	0.009%
2/8/2024	Mitsubishi UFJ Asset Management Co. Ltd.	8,714	$0.28M	0.0%	+12.3%	0.008%
2/7/2024	Jump Financial LLC	32,826	$1M	0.0%	-71.3%	0.031%
2/7/2024	BNP Paribas Financial Markets	243,605	$7.45M	0.0%	+13.6%	0.227%
2/7/2024	Teacher Retirement System of Texas	23,556	$0.72M	0.0%	-18.6%	0.022%
2/7/2024	E Fund Management Co. Ltd.	19,531	$0.60M	0.0%	+27.7%	0.018%
2/6/2024	Charles Schwab Investment Management Inc.	845,979	$25.89M	0.0%	+0.1%	0.787%
2/6/2024	Swiss National Bank	200,700	$6.14M	0.0%	-10.1%	0.187%
2/5/2024	Victory Capital Management Inc.	21,833	$0.67M	0.0%	-55.4%	0.020%
2/5/2024	Van ECK Associates Corp	2,395	$73K	0.0%	+22.9%	0.002%
2/5/2024	Retirement Systems of Alabama	327,453	$10.02M	0.0%	+0.1%	0.305%
2/5/2024	Russell Investments Group Ltd.	247,817	$7.58M	0.0%	+10.5%	0.231%
2/2/2024	State of New Jersey Common Pension Fund D	86,532	$2.65M	0.0%	-7.0%	0.081%
2/1/2024	Yousif Capital Management LLC	52,224	$1.60M	0.0%	+3.3%	0.049%
2/1/2024	New York State Common Retirement Fund	40,600	$1.24M	0.0%	-5.3%	0.038%
2/1/2024	Handelsbanken Fonder AB	21,600	$0.66M	0.0%	+7.5%	0.020%
2/1/2024	CWM LLC	103,014	$3.15M	0.0%	-5.2%	0.096%
1/31/2024	Beaumont Financial Advisors LLC	10,175	$0.31M	0.0%	-4.2%	0.009%
1/31/2024	Federated Hermes Inc.	7,430	$0.23M	0.0%	-17.9%	0.007%
1/30/2024	Strs Ohio	28,500	$0.87M	0.0%	+7.1%	0.027%
1/29/2024	Louisiana State Employees Retirement System	30,100	$0.92M	0.0%	N/A	0.028%
1/29/2024	WCM Investment Management LLC	172,865	$5.36M	0.0%	+13.6%	0.161%
1/29/2024	Friedenthal Financial	1,670	$51K	0.0%	N/A	0.002%
1/29/2024	Wealth Effects LLC	161,850	$4.95M	1.9%	-1.8%	0.151%
1/26/2024	Mutual of America Capital Management LLC	66,229	$2.03M	0.0%	-41.5%	0.062%
1/26/2024	Moody Aldrich Partners LLC	54,094	$1.66M	0.3%	-9.3%	0.050%
1/25/2024	Allspring Global Investments Holdings LLC	3,004	$92K	0.0%	-49.6%	0.003%
1/25/2024	International Assets Investment Management LLC	13,556	$0.44M	0.0%	N/A	0.013%
1/25/2024	Nisa Investment Advisors LLC	2,290	$70K	0.0%	-56.5%	0.002%
1/24/2024	Mirae Asset Global Investments Co. Ltd.	195,985	$6M	0.0%	-34.3%	0.182%
1/24/2024	International Assets Investment Management LLC	13,556	$0.44M	0.0%	N/A	0.013%
1/24/2024	Arizona State Retirement System	28,467	$0.87M	0.0%	-1.6%	0.026%
1/24/2024	China Universal Asset Management Co. Ltd.	12,429	$0.38M	0.1%	+351.5%	0.012%
1/19/2024	State of Alaska Department of Revenue	11,577	$0.35M	0.0%	-9.8%	0.011%
1/18/2024	Washington Trust Advisors Inc.	820	$25K	0.0%	N/A	0.001%
1/17/2024	Assenagon Asset Management S.A.	38,408	$1.18M	0.0%	-90.9%	0.036%
1/16/2024	Oak Ridge Investments LLC	43,644	$1.34M	0.2%	-8.4%	0.041%
1/16/2024	Pacer Advisors Inc.	16,119	$0.49M	0.0%	+79.7%	0.015%
1/16/2024	Raymond James Financial Services Advisors Inc.	11,484	$0.35M	0.0%	-46.5%	0.011%
1/16/2024	Raymond James & Associates	21,118	$0.65M	0.0%	-25.5%	0.020%
1/12/2024	SG Americas Securities LLC	34,720	$1.06M	0.0%	-73.0%	0.032%
1/10/2024	Nordea Investment Management AB	156,152	$4.86M	0.0%	-2.4%	0.145%
1/5/2024	Exchange Traded Concepts LLC	43,752	$1.34M	0.0%	N/A	0.041%
12/18/2023	Vanguard Group Inc.	10,858,315	$291.76M	0.0%	-1.0%	10.107%
12/13/2023	Teachers Retirement System of The State of Kentucky	34,942	$0.94M	0.0%	+101.4%	0.033%

Data available starting January 2016

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Today's Range

Now: $25.22

$24.30

$25.27

50 Day Range

MA: $26.93

$21.87

$36.08

52 Week Range

Now: $25.22

$20.67

$41.28

Volume

906,027 shs

Average Volume

1,394,640 shs

Market Capitalization

$3.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78

Who are the company insiders with the largest holdings of Arrowhead Pharmaceuticals?: Arrowhead Pharmaceuticals' top insider shareholders include:
Christopher Richard Anzalone (CEO)
Patrick O'brien (COO)
Kenneth Allen Myszkowski (CFO)
James C Hamilton (Insider)
Martin Javier San (Insider)
Douglas B Given (Director)
Tracie Oliver (Insider)
Hongbo Lu (Director)
Victoria Vakiener (Director)
William D Waddill (Director)
Adeoye Y Olukotun (Director)
Learn More about top insider investors at Arrowhead Pharmaceuticals.
Who are the major institutional investors of Arrowhead Pharmaceuticals?: Arrowhead Pharmaceuticals' top institutional shareholders include:
Principal Financial Group Inc. — 0.39%
Retirement Systems of Alabama — 0.28%
Assenagon Asset Management S.A. — 0.28%
Mirae Asset Global Investments Co. Ltd. — 0.26%
Swiss National Bank — 0.20%
Russell Investments Group Ltd. — 0.20%
Learn More about top institutional investors of Arrowhead Pharmaceuticals stock.
Which institutional investors are selling Arrowhead Pharmaceuticals stock?: During the last quarter, ARWR stock was sold by these institutional investors:
BNP Paribas Financial Markets
SG Americas Securities LLC
Russell Investments Group Ltd.
Nordea Investment Management AB
US Bancorp DE
Amalgamated Bank
Oak Ridge Investments LLC
Commonwealth Equity Services LLC
In the last year, company insiders that have sold Arrowhead Pharmaceuticals company stock include:
Christopher Richard Anzalone (CEO)
Patrick O'brien (COO)
Kenneth Allen Myszkowski (CFO)
James C Hamilton (Insider)
Martin Javier San (Insider)
Douglas B Given (Director)
Tracie Oliver (Insider)
Hongbo Lu (Director)
Learn More investors selling Arrowhead Pharmaceuticals stock.
Which institutional investors are buying Arrowhead Pharmaceuticals stock?: Within the last quarter, ARWR stock was acquired by institutional investors including:
Assenagon Asset Management S.A.
Mirae Asset Global Investments Co. Ltd.
Susquehanna Fundamental Investments LLC
Essex Investment Management Co. LLC
Principal Financial Group Inc.
WCM Investment Management LLC
Swiss National Bank
Global Assets Advisory LLC